Toragen Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for cancers caused by the human papillomavirus (HPV). The company is pioneering a first-in-class, oral small molecule inhibitor targeting the HPV E5 protein. Toragen has successfully completed a Phase 1 clinical trial in Stage 4 HPV+ head and neck cancer patients, achieving key safety and efficacy milestones.